Shin Fukudo

Shin Fukudo

Auto-generated profile, based on publicly available information

Shin Fukudo

Tohoku University

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Gastroenterology
Verified
Journal Article
Open access
PDF file
ASAmi D. Sperber
Ami D. Sperber
SBShrikant I. Bangdiwala
Shrikant I. Bangdiwala
DDDouglas A. Drossman
Douglas A. Drossman
UGUday C. Ghoshal
Uday C. Ghoshal
MSMagnus Simren
Magnus Simren
OPOlafur S. Palsson
Olafur S. Palsson
Background & Aims Although functional gastrointestinal disorders (FGIDs), now called disorders of gut-brain interaction, have major economic effects on health care systems and adversely affect quality of life, little is known about their global prevalence and distribution. We investigated the prevalence of and factors associated with 22 FGIDs, in 33 countries on 6 continents. Methods Data were collected via the Internet in 24 countries, personal interviews in 7 countries, and both in 2 countries, using the Rome IV diagnostic questionnaire, Rome III irritable bowel syndrome questions, and 80 items to identify variables associated with FGIDs. Data collection methods differed for Internet and household groups, so data analyses were conducted and reported separately. Results Among the 73,076 adult respondents (49.5% women), diagnostic criteria were met for at least 1 FGID by 40.3% persons who completed the Internet surveys (95% confidence interval [CI], 39.9–40.7) and 20.7% of persons who completed the household surveys (95% CI, 20.2–21.3). FGIDs were more prevalent among women than men, based on responses to the Internet survey (odds ratio, 1.7; 95% CI, 1.6–1.7) and household survey (odds ratio, 1.3; 95% CI, 1.3–1.4). FGIDs were associated with lower quality of life and more frequent doctor visits. Proportions of subjects with irritable bowel syndrome were lower when the Rome IV criteria were used, compared with the Rome III criteria, in the Internet survey (4.1% vs 10.1%) and household survey (1.5% vs 3.5%). Conclusions In a large-scale multinational study, we found that more than 40% of persons worldwide have FGIDs, which affect quality of life and health care use. Although the absolute prevalence was higher among Internet respondents, similar trends and relative distributions were found in people who completed Internet vs personal interviews.

4 February 2021 in Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
SFShin Fukudo
Shin Fukudo
TOToshikatsu Okumura
Toshikatsu Okumura
MIMasahiko Inamori
Masahiko Inamori
YOYusuke Okuyama
Yusuke Okuyama
MKMotoyori Kanazawa
Motoyori Kanazawa
KKKazuhiko Koike
Kazuhiko Koike
Managing irritable bowel syndrome (IBS) has attracted international attention because single-agent therapy rarely relieves bothersome symptoms for all patients. The Japanese Society of Gastroenterology (JSGE) published the first edition of evidence-based clinical practice guidelines for IBS in 2015. Much more evidence has accumulated since then, and new pharmacological agents and non-pharmacological methods have been developed. Here, we report the second edition of the JSGE-IBS guidelines comprising 41 questions including 12 background questions on epidemiology, pathophysiology, and diagnostic criteria, 26 clinical questions on diagnosis and treatment, and 3 questions on future research. For each question, statements with or without recommendations and/or evidence level are given and updated diagnostic and therapeutic algorithms are provided based on new evidence. Algorithms for diagnosis are requisite for patients with chronic abdominal pain or associated symptoms and/or abnormal bowel movement. Colonoscopy is indicated for patients with one or more alarm symptoms/signs, risk factors, and/or abnormal routine examination results. The diagnosis is based on the Rome IV criteria. Step 1 therapy consists of diet therapy, behavioral modification, and gut-targeted pharmacotherapy for 4 weeks. For non-responders, management proceeds to step 2 therapy, which includes a combination of different mechanistic gut-targeted agents and/or psychopharmacological agents and basic psychotherapy for 4 weeks. Step 3 therapy is for non-responders to step 2 and comprises a combination of gut-targeted pharmacotherapy, psychopharmacological treatments, and/or specific psychotherapy. These updated JSGE-IBS guidelines present best practice strategies for IBS patients in Japan and we believe these core strategies can be useful for IBS diagnosis and treatment globally.

1 January 2013 in BioPsychoSocial Medicine
Verified
Journal Article
Open access
PDF file
MKMichiko Kano
Michiko Kano
SFShin Fukudo
Shin Fukudo
Alexithymia is a personality trait characterized by difficulties in identifying and describing feelings and is associated with psychiatric and psychosomatic disorders. The mechanisms underlying the link between emotional dysregulation and psychosomatic disorders are unclear. Recent progress in neuroimaging has provided important information regarding emotional experience in alexithymia. We have conducted three brain imaging studies on alexithymia, which we describe herein. This article considers the role of emotion in the development of physical symptoms and discusses a possible pathway that we have identified in our neuroimaging studies linking alexithymia with psychosomatic disorders. In terms of socio-affective processing, alexithymics demonstrate lower reactivity in brain regions associated with emotion. Many studies have reported reduced activation in limbic areas (e.g., cingulate cortex, anterior insula, amygdala) and the prefrontal cortex when alexithymics attempt to feel other people’s feelings or retrieve their own emotional episodes, compared to nonalexithymics. With respect to primitive emotional reactions such as the response to pain, alexithymics show amplified activity in areas considered to be involved in physical sensation. In addition to greater hormonal arousal responses in alexithymics during visceral pain, increased activity has been reported in the insula, anterior cingulate cortex, and midbrain. Moreover, in complex social situations, alexithymics may not be able to use feelings to guide their behavior appropriately. The Iowa gambling task (IGT) was developed to assess decision-making processes based on emotion-guided evaluation. When alexithymics perform the IGT, they fail to learn an advantageous decision-making strategy and show reduced activity in the medial prefrontal cortex, a key area for successful performance of the IGT, and increased activity in the caudate, a region associated with impulsive choice. The neural machinery in alexithymia is therefore activated more on the physiologic, motor-expressive level and less in the cognitive-experiential domains of the emotional response system. Affects may play an important role in alleviating intrinsic physiologic reactions and adapting to the environment. Deficient development of emotional neural structures may lead to hypersensitivity to bodily sensations and unhealthy behaviors, a possible mechanism linking alexithymia to psychosomatic disorders.

1 November 2012 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
EAEmiko Aizawa
Emiko Aizawa
YSYasuhiro Sato
Yasuhiro Sato
TKTakanori Kochiyama
Takanori Kochiyama
NSNaohiro Saito
Naohiro Saito
MIMasahiro Izumiyama
Masahiro Izumiyama
SFShin Fukudo
Shin Fukudo

12 December 2014 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
SFShin Fukudo
Shin Fukudo
HKHiroshi Kaneko
Hiroshi Kaneko
HAHirotada Akiho
Hirotada Akiho
MIMasahiko Inamori
Masahiko Inamori
YEYuka Endo
Yuka Endo
TSTooru Shimosegawa
Tooru Shimosegawa

1 February 2016 in Gastroenterology
Verified
Journal Article
Open access
PDF file
SFShin Fukudo
Shin Fukudo
YKYoshikazu Kinoshita
Yoshikazu Kinoshita
TOToshikatsu Okumura
Toshikatsu Okumura
MIMotoko Ida
Motoko Ida
HAHiraku Akiho
Hiraku Akiho
KHKen Haruma
Ken Haruma
Background & Aims Previous studies have indicated that serotonin-3–receptor antagonists might have a sex-specific effect in patients with irritable bowel syndrome with diarrhea (IBS-D). Alosetron has been approved for the treatment of only women, and ramosetron has been approved for the treatment for only men. We performed a randomized, placebo-controlled, phase 3 study to determine whether ramosetron reduces symptoms of IBS-D in women. Methods We performed a prospective study of 576 female outpatients with IBS-D (according to the Rome III criteria), from February 2013 through February 2014, at 70 academic Gastroenterology Departments in Japan. After a 1-week baseline period, subjects received either 2.5 μg ramosetron (n = 292) or placebo (n = 284) once daily for 12 weeks. Primary end points were the monthly rates of response for relief from overall IBS symptoms and increased stool consistency at the last evaluation point. Quality of life (QOL) also was quantified. Results A significantly higher proportion of patients given ramosetron reported global improvement (50.7%; 95% confidence interval [CI], 44.8–56.6) than patients given placebo (32.0%; 95% CI, 26.7–37.8)—a difference of 18.6% (95% CI, 10.7–26.5; P < .001). The relative risk was 1.58 (95% CI, 1.29–1.94) and the number needed to treat was 6 (95% CI, 4–10). A significantly higher proportion of patients in the ramosetron group reported increased stool consistency (40.8%; 95% CI, 35.1%–46.6%) than in the placebo group (24.3%; 95% CI, 19.4%–29.7%)—a difference of 16.5% (95% CI, 8.9%–24.0%; P < .001). Patients receiving ramosetron had significant reductions in abdominal pain and discomfort (P = .001) and greater improvement in QOL (P = .002) compared with placebo. Ramosetron induced constipation in 11.0% of patients. Conclusions In a randomized, placebo-controlled study of 576 women with IBS-D, 2.5 μg ramosetron per day reduced symptoms and increased stool consistency and QOL. Clinicaltrials.gov no: NCT01870895.